Pembrolizumab (P) in patients (pts) with metastatic breast cancer (MBC) with high tumor mutational burden (HTMB): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.

Eyal Meiri,Elizabeth Garrett-Mayer,Susan Halabi,Pam K. Mangat,Sagun Shrestha,Eugene R. Ahn,Olufunlayo Osayameh,Venu Perla,Richard L. Schilsky

Pembrolizumab (P) in patients (pts) with metastatic breast cancer (MBC) with high tumor mutational burden (HTMB): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.

2019

Eyal Meiri
Elizabeth Garrett-Mayer
Susan Halabi
Pam K. Mangat
Sagun Shrestha
Eugene R. Ahn
Olufunlayo Osayameh
Venu Perla
Richard L. Schilsky

1014Background: TAPUR is a phase II basket study evaluating the anti-tumor activity of commercially available targeted agents in pts with advanced cancers with specific genomic alterations. P is an...

Keywords:

Oncology
Pathology
Pembrolizumab
Internal medicine
Medicine
Metastatic breast cancer
in patient
Colorectal cancer

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations